169 related articles for article (PubMed ID: 37939020)
1. Cyanine Dye Conjugation Enhances Crizotinib Localization to Intracranial Tumors, Attenuating NF-κB-Inducing Kinase Activity and Glioma Progression.
Pflug KM; Lee DW; Tripathi A; Bankaitis VA; Burgess K; Sitcheran R
Mol Pharm; 2023 Dec; 20(12):6140-6150. PubMed ID: 37939020
[TBL] [Abstract][Full Text] [Related]
2. The synthesis of a novel Crizotinib heptamethine cyanine dye conjugate that potentiates the cytostatic and cytotoxic effects of Crizotinib in patient-derived glioblastoma cell lines.
Choi PJ; Cooper E; Schweder P; Mee E; Faull R; Denny WA; Dragunow M; Park TI; Jose J
Bioorg Med Chem Lett; 2019 Sep; 29(18):2617-2621. PubMed ID: 31378572
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-κB-inducing kinase (NIK) and noncanonical NF-κB signaling.
Cherry EM; Lee DW; Jung JU; Sitcheran R
Mol Cancer; 2015 Jan; 14(1):9. PubMed ID: 25622756
[TBL] [Abstract][Full Text] [Related]
4. NEK2 enhances malignancies of glioblastoma via NIK/NF-κB pathway.
Xiang J; Alafate W; Wu W; Wang Y; Li X; Xie W; Bai X; Li R; Wang M; Wang J
Cell Death Dis; 2022 Jan; 13(1):58. PubMed ID: 35031599
[TBL] [Abstract][Full Text] [Related]
5. Cell-permeable NF-κB inhibitor-conjugated liposomes for treatment of glioma.
Zhang Y; Zhang L; Hu Y; Jiang K; Li Z; Lin YZ; Wei G; Lu W
J Control Release; 2018 Nov; 289():102-113. PubMed ID: 30243823
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral delivery of bortezomib: impact on survival in an intracranial glioma tumor model.
Wang W; Cho HY; Rosenstein-Sisson R; Marín Ramos NI; Price R; Hurth K; Schönthal AH; Hofman FM; Chen TC
J Neurosurg; 2018 Mar; 128(3):695-700. PubMed ID: 28409734
[TBL] [Abstract][Full Text] [Related]
7. Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy.
Zuckermann M; He C; Andrews J; Bagchi A; Sloan-Henry R; Bianski B; Xie J; Wang Y; Twarog N; Onar-Thomas A; Ernst KJ; Yang L; Li Y; Zhu X; Ocasio JK; Budd KM; Dalton J; Li X; Chepyala D; Zhang J; Xu K; Hover L; Roach JT; Chan KC; Hofmann N; McKinnon PJ; Pfister SM; Shelat AA; Rankovic Z; Freeman BB; Chiang J; Jones DTW; Tinkle CL; Baker SJ
Mol Cancer; 2024 Jun; 23(1):123. PubMed ID: 38849845
[TBL] [Abstract][Full Text] [Related]
8. Quercetin induces MGMT
Wang W; Yuan X; Mu J; Zou Y; Xu L; Chen J; Zhu X; Li B; Zeng Z; Wu X; Yin Z; Wang Q
Phytomedicine; 2023 Sep; 118():154933. PubMed ID: 37451151
[TBL] [Abstract][Full Text] [Related]
9. Essential role of cooperative NF-κB and Stat3 recruitment to ICAM-1 intronic consensus elements in the regulation of radiation-induced invasion and migration in glioma.
Kesanakurti D; Chetty C; Rajasekhar Maddirela D; Gujrati M; Rao JS
Oncogene; 2013 Oct; 32(43):5144-55. PubMed ID: 23178493
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib and erlotinib inhibits growth of c-Met
Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
[TBL] [Abstract][Full Text] [Related]
11. Dioscin decreases M2 polarization via inhibiting a positive feedback loop between RBM47 and NF-κB in glioma.
Bai J; Zhang X; Meng W; Xu H; Liu Y; Zhong Y; Lin X; Wang J; Fan D; Lv G; Gu Y
Phytomedicine; 2024 Jun; 128():155417. PubMed ID: 38518642
[TBL] [Abstract][Full Text] [Related]
12. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
13. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
14. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
[TBL] [Abstract][Full Text] [Related]
16. TBK1 Inhibitor Exerts Antiproliferative Effect on Glioblastoma Multiforme Cells.
Scuderi SA; Lanza M; Casili G; Esposito F; Colarossi C; Giuffrida D; Irene P; Cuzzocrea S; Esposito E; Campolo M
Oncol Res; 2021 Sep; 28(7):779-790. PubMed ID: 33741083
[TBL] [Abstract][Full Text] [Related]
17. Alantolactone, a natural sesquiterpene lactone, has potent antitumor activity against glioblastoma by targeting IKKβ kinase activity and interrupting NF-κB/COX-2-mediated signaling cascades.
Wang X; Yu Z; Wang C; Cheng W; Tian X; Huo X; Wang Y; Sun C; Feng L; Xing J; Lan Y; Sun D; Hou Q; Zhang B; Ma X; Zhang B
J Exp Clin Cancer Res; 2017 Jul; 36(1):93. PubMed ID: 28701209
[TBL] [Abstract][Full Text] [Related]
18. CRB2 enhances malignancy of glioblastoma via activation of the NF-κB pathway.
Wang Y; Bao G; Zhang M; Xiang J; Zhou H; Wahafu A; Wu W; Ma X; Huo L; Bai X; Xie W; Liu P; Wang M
Exp Cell Res; 2022 May; 414(1):113077. PubMed ID: 35219647
[TBL] [Abstract][Full Text] [Related]
19. NF-κB-induced IL-6 ensures STAT3 activation and tumor aggressiveness in glioblastoma.
McFarland BC; Hong SW; Rajbhandari R; Twitty GB; Gray GK; Yu H; Benveniste EN; Nozell SE
PLoS One; 2013; 8(11):e78728. PubMed ID: 24244348
[TBL] [Abstract][Full Text] [Related]
20. Nuclear factor-κB in glioblastoma: insights into regulators and targeted therapy.
Cahill KE; Morshed RA; Yamini B
Neuro Oncol; 2016 Mar; 18(3):329-39. PubMed ID: 26534766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]